Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children (ESPHALL)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Ministry of Health, France
Novartis
Information provided by (Responsible Party):
Rennes University Hospital
ClinicalTrials.gov Identifier:
NCT00287105
First received: February 3, 2006
Last updated: February 17, 2015
Last verified: February 2015
  Purpose

The purpose of this study is to determine whether Imatinib is safe and effective in association with intensive treatment of Ph+ALL in children.


Condition Intervention Phase
Acute Lymphoblastic Leukemia
Philadelphia Chromosome
Drug: Standard chemotherapy + Imatinib
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Phase II Study to Explore the Safety and Efficacy of Imatinib With Chemotherapy in Pediatric Patients With Ph+ / BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL)

Resource links provided by NLM:


Further study details as provided by Rennes University Hospital:

Primary Outcome Measures:
  • Disease free survival (DFS). DFS will be calculated as the time from inclusion to either one of the following events: relapse, death in CCR, second malignancies. [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Compare long term outcome between patients treated by BFM-chemotherapy and patient undergoing more intensive chemotherapy (protocole COGAALL0031 : Children Oncology Group-USA). [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Long-term clinical outcome : Disease free survival (DFS), Event-Free Survival (EFS) and Overall Survival (OS) in each risk groups. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Pattern of molecular response (MRD) [ Time Frame: 5 time points between S4 and S22 ] [ Designated as safety issue: No ]
  • Conversion rate to CR in patients resistant to the first part of the induction phase of chemotherapy included in the Poor-risk group. [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 110
Study Start Date: February 2006
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Good risk Ph+ALL
For protocols which adopt a steroid prephase: patients who are Prednisone-good responder and achieve CR after the induction course. For protocols which do not adopt steroid prephase: patients who have M1/M2 BM at day 15 or M1 BM at day 21 and achieve CR after the induction course. Expected stratification in this group: 70-75%.
Drug: Standard chemotherapy + Imatinib
Patients receive Imatinib together with the standard chemotherapy regimen of phase IB and after each of three consecutive blocks of the standard chemotherapy in the consolidation phase
Other Names:
  • Glivec
  • Gleevec
Poor risk Ph+ALL
For protocols which adopt a steroid prephase: patients who are Prednisone poor-responders. For protocol which do not adopt a steroid prephase: patients who have M3 BM at day 15 or M2/M3 BM at day 21. For all protocols: patients who do not achieve CR after the induction course. Expected stratification: 25-30%.
Drug: Standard chemotherapy + Imatinib
Patients receive Imatinib together with the standard chemotherapy regimen of phase IB and after each of three consecutive blocks of the standard chemotherapy in the consolidation phase
Other Names:
  • Glivec
  • Gleevec

Detailed Description:

Recent advances in treatment have increased the cure of childhood ALL to 75% or better. However, attempts to improve results for resistant subtypes of ALL, such as Ph+ ALL, have been largely unsuccessful. Imatinib, an inhibitor of protein-tyrosine kinases, is currently being tested in several phase I, II and III trials covering most Chronic Myeloid Leukemia patient populations and patients with overtly relapsed or refractory Ph+ALL. Pediatric patients with Ph+ALL will receive Imatinib, added to intensive, post-induction BFM-type chemotherapy. The endpoint will be the evaluation on the long-term clinical outcome, in particular on the Disease Free Survival (DFS).

  Eligibility

Ages Eligible for Study:   1 Year to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Children and adolescents aged 1 to 17 years at diagnostic
  • Documented Ph+ ALL
  • Eligibility for the current local prospective therapeutic study of childhood ALL
  • Informed consent given by the parents or by legal guardian

Exclusion Criteria:

  • Abnormal hepatic functions
  • Abnormal renal functions
  • Active systemic bacterial, fungal or viral infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00287105

Locations
France
Service d'hématologie pédiatrique CHRU
Amiens, France, 80080
Service hématologie pédiatrique Hôpital Saint-Jacques
Besancon, France, 25000
Service d'hémato-oncologie - Hôpital des Enfants Pellegrin
Bordeaux, France, 33076
Hôpital Morvan
Brest, France, 29200
Hématologie oncologie pédiatrique-CHU Caen
Caen, France
Hémato-Oncologie et Thérapie Cellulaire Pédiatrique - Hôtel Dieu
Clermont-Ferrand, France, 63058
Dijon hôpital d'enfants
Dijon, France, 21034
Hémato-Oncologie Pédiatrique - Hôpital d'Enfants
Dijon, France, 21034
Pédiatrie CHU - Hôpital Nord
Grenoble, France, 38043
Hôpital Jeanne de Flandre
Lille, France, 59037
Limoges University Hospital
Limoges, France, 87042
Hôpital DEBROUSSE Institut d'hématologie et d'oncologie pédiatrique
Lyon, France
Service hématologie pédiatrique CHU la Timone
Maseille, France, 13385
Hôpital Arnaud de Villeneuve
Montpellier, France
CHR Hôtel Dieu
Nantes, France
Hôpital de l'Archet
Nice, France
Service hématologie Hopital Necker
Paris, France, 75015
Hémato-immunologie-Robert Debré
Paris, France
Hématologie Pédiatrique - Hôpital Trousseau
Paris, France, 75571
Hématologie Hôpital Jean Bernard
Poitiers, France, 86021
Hématologie pédiatrique-Hopital américain
Reims, France
Service d'hématologie pédiatrique - Hôpital Sud
Rennes, France, 35033
Service d'Immuno Hémato Oncologie Pédiatrique - Hôpital Charles Nicolle
Rouen, France, 76031
Hématologie, Oncologie pédiatrique-CHU Saint Etienne
Saint Etienne, France
Pédiatrie Hôpital Hautepierre
Strasbourg, France, 67098
Hopital des enfants
Toulouse, France
CHU- Centre Gatien de Clocheville
Tours, France, 37044
Hôpital d'enfants
Vandoeuvre Les Nancy, France, 54511
Sponsors and Collaborators
Rennes University Hospital
Ministry of Health, France
Novartis
Investigators
Study Director: Andrea Biondi, MD Ospedale S. Gerardo - Monza
Principal Investigator: Virginie Gandemer, MD Rennes University Hospital
  More Information

No publications provided by Rennes University Hospital

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Rennes University Hospital
ClinicalTrials.gov Identifier: NCT00287105     History of Changes
Other Study ID Numbers: EUDRACT 2004-001647-30, PHRC/04-04, CIC0203/043
Study First Received: February 3, 2006
Last Updated: February 17, 2015
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Rennes University Hospital:
Chemotherapy
Leukemia
Children
Philadelphia chromosome
Protein-tyrosine kinase inhibitor

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphoid
Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Chromosome Aberrations
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Translocation, Genetic
Imatinib
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on June 29, 2015